StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen Accrued Other Deductions Reserve by Year

Accrued Other Deductions Reserve (Cash Discounts & Co-Pay) — Ending Balance ($M) ($M)

Amgen Accrued Other Deductions Reserve: $469M in FY2025, up 10.1% from a year earlier. That is the highest of the 13 years on record here.

Latest, FY2025
469
Period ended Dec 31, 2025
Change on a year earlier
+10.1%
426 in FY2024
History
13 years
Since FY2013
Sources
10
Documents cited below

Where the FY2025 figure comes from

“|| Balance as of December 31, 2025 | $ | 8,839 | $ | 1,298 | $ | 469 | $ | 10,606”

Source: Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗

Reported in Form 10-K Item 7 MD&A Critical Accounting Estimates — Gross-to-Net Sales Deductions Rollforward.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Amgen Accrued Other Deductions Reserve ($M), annual FY2013–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gtn-bal-other

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.